Recent advances towards the discovery of dopamine receptor ligands
- 25 April 2006
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 16 (5) , 587-630
- https://doi.org/10.1517/13543776.16.5.587
Abstract
Dopamine is a key regulator in the CNS, contributing importantly to functions of arousal and attention, initiation of movement, perception, motivation and emotion. Its imbalance has been implicated in the pathophysiology, and more clearly in the pharmacology, of a number of neurobehavioural disorders, including Parkinson’s disease, schizophrenia, mania and depression, alcohol and drug abuse, as well as attention and eating disorders. Five major dopamine receptor subtypes (D1 – D5) have been identified, with distinct differences in their genes and peptide composition, molecular functions and neuropharmacology. These receptors represent the rational targets for the treatment of a large number of neurological and psychiatric disorders. In recent years, substantial efforts have addressed the most recently described dopamine receptor types, particularly types D3, D4 and D5, although most research involves the longer-known D1 and D2 dopamine receptors. Current pharmacological efforts in medicinal chemistry and ...Keywords
This publication has 83 references indexed in Scilit:
- Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's diseaseThe Lancet Neurology, 2004
- In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐racloprideSynapse, 2004
- Strategy for Modulation of Central Dopamine Transmission Based on the Partial Agonist Concept in Schizophrenia TherapyThe Japanese Journal of Pharmacology, 2001
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Both splicing variants of the dopamine D2 receptor mRNA are up-regulated by antipsychotic drugsNeuroscience Letters, 1993
- A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleusNature, 1990
- Dopamine receptor subtype imbalance in schizophreniaLife Sciences, 1987
- The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmosetNeuroscience Letters, 1985
- Synthesis and dopaminergic activity of (R)- and (S)-4-hydroxy-2-(di-n-propylamino)indanJournal of Medicinal Chemistry, 1985